Neoadjuvant FOLFIRINOX versus Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Cancer: Update on the Nationwide Multicenter PREOPANC-2 Randomized Trial. (2021)